Concert Pharmaceuticals Inc. (CNCE) Stock Price Down 2.5%
Shares of Concert Pharmaceuticals Inc. (NASDAQ:CNCE) traded down 2.5% during trading on Friday . The stock traded as low as $11.21 and last traded at $11.47, with a volume of 56,462 shares trading hands. The stock had previously closed at $11.77.
Several analysts recently commented on the stock. Brean Capital reissued a “buy” rating on shares of Concert Pharmaceuticals in a research note on Saturday, April 30th. Zacks Investment Research raised shares of Concert Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 4th. Finally, Stifel Nicolaus assumed coverage on shares of Concert Pharmaceuticals in a research note on Friday, July 1st. They set a “buy” rating and a $23.00 target price for the company. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $26.43.
The stock has a market cap of $255.26 million and a price-to-earnings ratio of 13.79. The stock’s 50 day moving average price is $11.52 and its 200-day moving average price is $13.11.
Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.18. Equities research analysts forecast that Concert Pharmaceuticals Inc. will post ($2.16) EPS for the current fiscal year.
In related news, CEO Roger D. Tung acquired 19,610 shares of the stock in a transaction on Wednesday, May 11th. The stock was purchased at an average price of $10.55 per share, for a total transaction of $206,885.50. Following the transaction, the chief executive officer now owns 538,965 shares of the company’s stock, valued at approximately $5,686,080.75. The acquisition was disclosed in a filing with the SEC, which is available through this link.
An institutional investor recently raised its position in Concert Pharmaceuticals stock. Dimensional Fund Advisors LP increased its stake in shares of Concert Pharmaceuticals Inc. (NASDAQ:CNCE) by 405.9% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 224,348 shares of the company’s stock after buying an additional 179,998 shares during the period. Dimensional Fund Advisors LP owned 1.02% of Concert Pharmaceuticals worth $4,256,000 as of its most recent filing with the SEC.
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.